Summarized by Masters of Longevity from Longevity Technology.
Mission Therapeutics’ dosing milestone marks an update-style article on an early-stage Parkinson’s clinical trial, offering trial scope and next steps.
Key Takeaways
- The MTX325-101 Phase 1b trial has dosed its first Parkinson’s patient and will enrol 36 participants.
- The study will assess safety, tolerability, biomarkers, imaging, and clinical proof-of-mechanism across multiple countries.
- A data readout from the trial is anticipated in late 2027.
